학술논문
A Comparative Study between cefpirome (CPR) and ceftazidime (CAZ) in Respiratory Tract Infections / 呼吸器感染症に対するcefpirome sulfate (CPR) とceftazidime の薬効比較試験
Document Type
Journal Article
Author
Akihiko SAKAUE; Akira MIWA; Akira SAITO; Akira SUZUKI; Akira WATANABE; Atsuko YANADA; Atsushi SAITO; Choei ITO; Eiichi SAKAI; Eiro TSUBURA; Etsuro YAMAGUCHI; Fumikazu UMEDA; Fumio MATSUMOTO; Fumio MIKI; Fumitaka OGUSHI; Fumiyuki KUZE; Hajime GOTO; Harumi SHISHIDO; Hideaki SHIGENO; Hidekazu SAWADA; Hidenori KUMANO; Hideo MIYASHITA; Hideo SASAKI; Hidetoshi SHIBAKI; Hideya MURABAYASHI; Hirofumi FUKUHARA; Hiromi TOMIOKA; Hironobu IWASAKI; Hironobu KOGA; Hiroshi FUKUHARA; Hiroshi KANESHIMA; Hiroshi MIURA; Hiroshi OSHITANI; Hiroshi TAKAHASHI; Hiroshi YAMADA; Hirotaka YASUBA; Hiroyasu BANDO; Hiroyuki KOBAYASHI; Hiroyuki MATSUMOTO; Hiroyuki NAGAI; Hitoshi NAGAI; Hitoshi TANAKA; Ichiro NAKAYAMA; Iwao SAKURAI; Izumi HAYASHI; Izumi KOYAMA; Jingoro SHIMADA; Jiro HINO; Jun GOTO; Kaneo SUZUKI; Kanzaburo MATSUMURA; Kaoru SHIMADA; Katsuhiro SUZUKI; Katsumi ENDO; Katsumi OKUDAIRA; Katsuro YAGAWA; Katsuyoshi SHIMOJI; Kazuhide YAMAMOTO; Kazuhito MIZUNO; Kazuki KONISHI; Kazuo SATO; Kazuo TAKAOKA; Kazuo TAKEBE; Keiichi MIKASA; Keisuke ONUKI; Keizo KITSUKAWA; Keizo MATSUMOTO; Keizo YAMAGUCHI; Kenichi IMAMURA; Kenichi TAKAHASHI; Kenichi YAMAKI; Kenji BANDO; Kenji KONO; Kenzo TAKAGI; Kikuo SUGIMOTO; Kiwao WATANABE; Kiyoshi KONNO; Kiyoshi SHIMA; Kiyoyasu FUKUSHIMA; Kohei HARA; Koichi SHINOHARA; Koichi WADA; Koichiro NAKATA; Koji NARUI; Koji TAKAGI; Koji TANEICHI; Kojiro YASUNAGA; Kosaku NAGAI; Kotaro OIZUMI; Kou MUROHASHI; Koya SHIBA; Kuniharu SHIDA; Kunio KUDO; Kyuichiro SEKINE; Makoto KIMURA; Masaaki ARAKAWA; Masaharu SUGIYAMA; Masahide SHINOHARA; Masahide TAKII; Masakazu TAKASUGI; Masaki HIROTA; Masaki YOSHIDA; Masakichi MOTOMIYA; Masanaga TAKATO; Masanobu KAJI; Masanori MATSUMURA; Masao KADO; Masaru CHIBA; Masaru NAKAGAWA; Masaru NASU; Masaru SUMI; Masashi KAWAHARA; Masashi KAWANISHI; Masashi TAMURA; Masatoshi IMAI; Masayasu KAWANISHI; Masayoshi SAWAKI; Masayuki NOGUCHI; Masayuki OURA; Masumi BABA; Masumi TOMIZAWA; Michitaka SHIMURA; Mieko GOTO; Mikio TAGUCHI; Mitsuhide OMICHI; Mitsunobu AKASHI; Mitsuo KAKU; Mitsuo MASUDA; Mitsuo SATO; Mitsuru KONISHI; Morio SUDO; Moritoshi AKIYAMA; Motokazu KATO; Munehiko ISHII; Naofumi SUYAMA; Niro OKIMOTO; Nobuaki SHIGEMATSU; Nobuhiro NARITA; Nobuhiro SASAKI; Nobuhisa SATO; Nobuki AOKI; Nobuya OGAWA; Nobuyuki SHIMONO; Osamu EBISUI; Osamu SAKAI; Rinzo SOEJIMA; Riyo YAMAGUCHI; Ryujiro SUZUKI; Satoshi FUJIUCHI; Satoshi SHINDO; Seibun YONEZU; Seiichi MURAKAMI; Seiji HORI; Seiji TAKEDA; Seiko ISHIKAWA; Shigeki ODAGIRI; Shigeru KONO; Shigeru OCHIAI; Shinichi TOHARA; Shinichiro HAYASHI; Shinobu TAKENAKA; Shinya YASUDA; Shoji KASAGI; Shunsaku OHSHIMA; Sokichi ONODERA; Sunao ISHIDA; Susumu ITO; Tadasu KURIMURA; Taiji YOSHIDA; Takafumi OTA; Takako MURAYAMA; Takao SASAKI; Takashi INOUE; Takashi KAWASHIMA; Takashi MOURI; Takashi NISHIMURA; Takashi OGURA; Takashi YOSHIKAWA; Takayoshi TASHIRO; Takeo IMAI; Takeshi BANDO; Takeshi OGURA; Tamotsu TAKISHIMA; Tatsuki OYAIZU; Tatsuo NAKATANI; Tatsuo SATAKE; Teruaki YOSHIOKA; Teruo HASUIKE; Tetsuji KOROKU; Tetsuo SHIMIZU; Tetsuro UNOURA; Toru YAMAZAKI; Toshiaki FUJIKANE; Toshiaki HAYASHI; Toshiaki SHISHIDO; Toshiaki TSUNODA; Toshiaki YOSHIDA; Toshiharu MATSUSHIMA; Toshihiko TAKEUCHI; Toshiyuki ISHIMARU; Toyokazu TAMURA; Tsugio TERAI; Tsuyoshi KIKUIRI; Tsuyoshi NAGATAKE; Waka ICHIKAWA; Yasufumi MIYAMOTO; Yasuhito HONDA; Yasumasa DOTSU; Yasuo ARAI; Yasuo ONO; Yasuo TANNO; Yasuo YAMADA; Yasuyuki SANO; Yoichiro GOTO; Yoichiro ICHIKAWA; Yomei HIRAGA; Yoshiaki WATANABE; Yoshihiro HASHIMOTO; Yoshihiro TAKISHITA; Yoshihiro UEDA; Yoshikazu KAWAKAMI; Yoshimitsu HAYASHI; Yoshinobu OSAKI; Yoshiro SAWAE; Yoshitaka NAKAMORI; Yoshiteru SHIGENO; Yuei IRABU; Yuji SUGIMOTO; Yukio MATSUMOTO; 三木 文雄; 三浦 洋; 三笠 桂一; 三輪 映; 上田 良弘; 下地 克佳; 下野 信行; 中井 準; 中山 一朗; 中川 勝; 中森 祥隆; 中田 紘一郎; 中谷 龍王; 丹野 恭夫; 久世 文幸; 井上 尚志; 今井 健郎; 今井 昌利; 今村 憲市; 今野 淳; 伊良部 勇栄; 伊藤 進; 伊藤 長英; 佐々木 信博; 佐々木 孝夫; 佐々木 英夫; 佐竹 辰夫; 佐藤 信久; 佐藤 光男; 佐藤 和男; 佐野 靖之; 兼島 洋; 冨岡 洋海; 副島 林造; 加地 正伸; 加藤 元一; 千葉 秀; 原 耕平; 古西 満; 古賀 宏延; 吉岡 照晃; 吉川 隆志; 吉田 俊昭; 吉田 正樹; 吉田 泰二; 向野 賢治; 和田 光一; 坂上 明彦; 坂井 英一; 坂東 弘康; 坂東 憲司; 坂東 武志; 堀 誠治; 増田 光男; 大串 文隆; 大島 駿作; 大崎 能伸; 大泉 耕太郎; 大浦 雅之; 大道 光秀; 太田 貴文; 奥平 克己; 安場 広高; 安永 幸二郎; 安田 悳也; 宍戸 春美; 宍戸 稔聡; 室橋 光宇; 宮下 英夫; 宮本 康文; 富沢 磨須美; 寺井 継男; 小倉 剛; 小倉 高志; 小六 哲司; 小山 泉; 小川 暢也; 小林 宏行; 小柳津 竜樹; 小田切 繁樹; 小西 一樹; 小貫 圭介; 小野寺 壮吉; 山口 恵三; 山口 悦郎; 山口 理世; 山崎 透; 山木 健市; 山本 和英; 山田 保夫; 山田 洋; 岩崎 博信; 岳中 耐夫; 島田 馨; 嶋田 甚五郎; 川上 義和; 川原 正士; 川島 崇; 川西 正泰; 川西 雅士; 工藤 国夫; 市川 和加; 市川 洋一郎; 平賀 洋明; 廣田 正毅; 後藤 元; 後藤 純; 後藤 美江子; 後藤 陽一郎; 志摩 清; 志村 道隆; 志田 國治; 戎井 理; 成井 浩司; 成田 亘啓; 戸原 震一; 押谷 浩; 斎藤 厚; 斎藤 篤; 斧 康雄; 新藤 哲; 日野 二郎; 明石 光伸; 普久原 浩; 木村 丹; 本宮 雅吉; 本田 泰人; 杉山 正春; 杉本 勇二; 杉本 幾久雄; 村上 誠一; 村山 尚子; 村林 秀哉; 松島 敏春; 松本 博之; 松本 慶蔵; 松本 文夫; 松本 行雄; 松村 寛三郎; 松村 正典; 林 嘉光; 林 敏明; 林 泉; 林 真一郎; 柴 孝也; 栗村 統; 桜井 馨; 梁田 敦子; 梅田 文一; 橋本 吉弘; 橘川 桂三; 武内 俊彦; 武田 誠司; 武部 和夫; 毛利 孝; 水野 和人; 永井 寛之; 永武 毅; 沖本 二郎; 河野 茂; 清水 哲雄; 渡辺 好明; 渡辺 彰; 渡辺 貴和雄; 滝下 佳寛; 澤木 政好; 澤江 義郎; 澤田 秀和; 瀧井 昌英; 瀧島 任; 熊野 英典; 田中 斉; 田代 隆良; 田口 幹雄; 田村 昌士; 田村 豊一; 矢川 克郎; 石丸 敏之; 石井 宗彦; 石川 聖子; 石田 直; 福原 弘文; 福島 喜代康; 秋山 盛登司; 種市 幸二; 笠置 商次; 篠原 弘一; 篠原 正英; 米津 精文; 芝木 秀俊; 荒井 康男; 荒川 正昭; 菊入 剛; 落合 滋; 蓮池 照夫; 藤兼 俊明; 藤内 智; 螺良 英郎; 西村 尚志; 角 優; 角田 俊昭; 賀来 満夫; 道津 安正; 遠藤 勝実; 那須 勝; 酒井 紀; 重松 信昭; 重野 秀明; 重野 芳輝; 野口 昌幸; 鈴木 光; 鈴木 克洋; 鈴木 周雄; 鈴木 明; 鈴木 隆二郎; 長井 弘策; 門 政男; 関根 球一郎; 隆杉 正和; 青木 信樹; 須山 尚史; 須藤 守男; 馬場 ますみ; 高岡 和夫; 高木 健三; 高木 宏治; 高橋 健一; 高橋 宏; 高頭 正長; 鵜浦 哲朗; 齋藤 玲
Source
感染症学雑誌 / Kansenshogaku Zasshi. 1991, 65(4):400
Subject
Language
Japanese
ISSN
0387-5911
1884-569X
1884-569X
Abstract
Efficacy and safety of a new injectable cephem antibiotic, cefpirome sulfate (hereafter, CPR), against respiratory tract infections were examined and compared with those of a control drug, ceftazidime (hereafter, CAZ). As a rule, CPR 0.5 g twice a day, 1.0 g twice a day, or CAZ 1.0 g twice a day (hereafter CPR 0.5 g group, CPR 1.0 g group, and CAZ group) was administered for 14 days and the following results were obtained.1. The total number of cases was 470 (155 cases in the CPR 0.5 g group, 160 cases in the CPR 1.0 g group, and 155 cases in the CAZ group). Among them 390 cases were subjected to analyses of clinical efficacy by the efficacy evaluation committee (131 cases in the CPR 0.5 g group, 131 cases in the CPR 1.0 g group and 128 cases in the CAZ group).2. Efficacy rates determined by the efficacy evaluation committee were 82.4%(108/131) for the CPR 0.5 g group, 81.7%(107/131) for the CPR 1.0 g group, and 83.6%(107/128) for the CAZ group. Efficacy rates determined by the physician in charge were 82.0% (105/128) for the CPR 0.5 g group, 80.5%(99/123) for the CPR 1.0 g group, and 88.5%(108/122) for the CAZ group. No statistically significant difference was observed among the 3 groups. In evaluation of equivalency, clinical efficacy for the CPR 0.5 g group and the CPR 1.0 g group determined by the clinical efficacy evaluation committee was proved to be statistically equivalent to that for the CAZ group.3. In patients with pneumonia, efficacy rates determined by the efficacy evaluation committee were 87.1%(61/70) for the CPR 0.5 g group, 80.7%(71/88) for the CPR 1.0 g group, and 78.9%(56/71) for the CAZ group. Efficacy rates determined by the physician in charge were 85.3%(58/68) for the CPR 0.5 g group, 80.7%(67/83) for the CPR 1.0 g group, and 86.2%(56/65) for the CAZ group and no statistically significant difference was observed among the 3 groups. In patients with chronic respiratory tract infection, efficacy rates determined by the efficacy evaluation committee were 77.0%(47/61) for the CPR 0.5 g group, 83.7%(36/43) for the CPR 1.0 g group, and 89.5% (51/57) for the CAZ group. Efficacy rates determined by the physician in charge were 78.3%(47/60) for the CPR 0.5 g group, 80.0%(32/40) for the CPR 1.0 g group, and 91.2%(52/57) for the CAZ group. No statistically significant difference was observed among the 3 groups.4. Bacteriological efficacy was judged by bacterial eradication rates, which were 86.6%(58 strains out of 67 strains) for the CPR 0.5 g group, 87.9% (58 strains out of 66 strains) for the CPR 1.0 g group, and 93.0% (66 strains out of 71 strains) for the CAZ group. No statistically significant difference was observed among the 3 groups.5. Adverse events occurred in 3 (2.1%) of the CPR 0.5 g group patients, 8 (5.6%) of the CPR 1.0 g group patients, and 9 (6.4%) of the CAZ group patients. No statistically significant difference was observed among the 3 groups. The incidences of abnormal laboratory findings were 21.3%(29/136) for the CPR 0.5 g group, 35.7%(46/129) for the CPR 1.0 g group and 24.8%(32/129) for the CAZ group and there was significant difference among the incidences of the 3 groups. Multiple comparison demonstrated that neither the CPR 0.5 g group nor the CPR 1.0 group was significantly different from the CAZ group in the incidence but the CPR 1.0 g group showed a significantly higher incidence of abnormal laboratory findings than the CPR 0.5 g group (p<0.05).6. Utility rates determined by the efficacy evaluation committee were 81.1%(107/132) for the CPR 0.5 g group, 79.5%(105/132) for the CPR 1.0 g group, and 79.2%(103/130) for the CAZ group. No statistically significant difference was observed among the 3 groups. Utility rates for pneumonia and chronic respiratory tract infection were not significantly different among the 3 groups.